Skip to content
Disclosery

Vida Ventures Advisors, LLC

Follow

13F filer, CIK 1831423, BOSTON, MA

Vida Ventures Advisors, LLC reported $138,598,114 across 6 holdings for the quarter ended 2024-09-30, in a 13F-HR filed 2024-10-08.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-24-009559

Period
2024-09-30
Reported value
$139M
Holdings
6
Top 10 weight
100%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TECXnew+1,028,674$31.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q3 2024

Share positions as resolved from 13F-HR 0000950123-24-009559, largest first. % of portfolio is the value over $138,598,114, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 3,931,818 shares; 2024Q1: 3,931,818 shares; 2024Q2: 3,931,818 shares; 2024Q3: 3,931,818 shares 3,931,818$62.9M45.36%0Timeline
TECXTECTONIC THERAPEUTIC INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: not reported; 2024Q2: not reported; 2024Q3: 1,028,674 shares 1,028,674$31.2M22.49%newTimeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: 4,523,924 shares; 2024Q2: 4,523,924 shares; 2024Q3: 4,523,924 shares 4,523,924$22.1M15.96%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 2,074,787 shares; 2024Q1: 407,499 shares; 2024Q2: 407,499 shares; 2024Q3: 407,499 shares 407,499$14.6M10.56%0Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,798,163 shares; 2024Q1: 1,798,163 shares; 2024Q2: 1,798,163 shares; 2024Q3: 1,798,163 shares 1,798,163$5.03M3.63%0Timeline
KRONOS BIO INCKRONOS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 2,765,314 shares; 2024Q1: 2,765,314 shares; 2024Q2: 2,765,314 shares; 2024Q3: 2,765,314 shares 2,765,314$2.77M2%0

How Q3 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-24-009559 base2024-10-08acceptance time not in the bulk data set